Beactica expands its drug discovery collaboration with Boehringer Ingelheim
Uppsala, Sweden, 22 October 2013
Beactica today announced that it has expanded its collaboration with Boehringer Ingelheim. For the additional project, Beactica will use its proprietary fragment-based platform to identify novel and selective hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim. Financial terms of the agreement were not disclosed.
"We are pleased to expand our work with Boehringer Ingelheim and look forward to further supporting them in their discovery of innovative, new medicines for the treatment of cancer”, said Beactica CEO, Dr Per Källblad. "The collaboration builds on Beactica's strategy of establishing long-term relationships with leading pharmaceutical companies and validates the potential of our drug discovery platform”.
Beactica's collaboration with Boehringer Ingelheim was established in 2008. Previous work under the collaboration includes the contribution of important insights into the interaction mechanism of Giotrif® (afatinib), a treatment that has been recently approved for lung cancer patients with EGFR mutations in Europe and the US.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in oncology and CNS, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as the leader in fragment-based drug discovery using SPR biosensor technology.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information, please visit: www.boehringer-ingelheim.com